FPF
GBT

FNY Partners Fund’s Global Blood Therapeutics, Inc. GBT Stock Holding History

FNY Partners Fund’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,784
Closed -$65K – 1272
2017
Q1 		$65K Buy
+1,784
New +$44.9K 0.01% 639

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FNY Partners Fund's GBT Position: Q1 2018 in Review

FNY Partners Fund sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2018, closing a stake of 100 shares — an estimated $3K sold.

FNY Partners Fund first reported a position in GBT in Q1 2017 and held it in 4 quarters. The position peaked at $65K in Q3 2017. 176 funds tracked by Wall St. Rank hold GBT as of Q1 2018.

  • FNY Partners Fund reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • FNY Partners Fund sold 100 Global Blood Therapeutics, Inc. shares in Q1 2018, an estimated $3K.
  • FNY Partners Fund first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
  • FNY Partners Fund's Global Blood Therapeutics, Inc. position peaked at $65K in Q3 2017.
  • 176 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.